Evidence map›Paper›PMID 24694276›Full record

ArticleActa orthopaedica2014

Excellent results with the cemented Lubinus SP II 130-mm femoral stem at 10 years of follow-up: 932 hips followed for 5-15 years.

Wybren Prins, Remco Meijer, Boudewijn J Kollen, Cees Cpm Verheyen, Harmen B Ettema

Abstract readEvaluation Study
In one paragraph

Article in Acta orthopaedica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Experience of an anatomic femoral stem in a UK orthopaedic centre beyond 20 years of follow-up.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wybren PrinsDepartment of Orthopedic Surgery and Traumatology , Isala Klinieken , Zwolle.
Remco Meijer
Boudewijn J Kollen
Cees Cpm Verheyen
Harmen B Ettema

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe Lubinus SP II stem is well documented in both orthopedic registries and clinical studies. Worldwide, the most commonly used stem lengths are 150 mm and 170 mm. In 1995, the 130-mm stem was introduced, but no outcome data have been published. We assessed the long-term survival of the Lubinus SP II 130-mm stem in primary total hip arthroplasty. PATIENTS AND

methodsIn a retrospective cohort study, we evaluated 829 patients with a Lubinus SP II primary total hip arthroplasty (932 hips). The hips were implanted between 1996 and 2001. The primary endpoint was revision for any reason. The mean follow-up period was 10 (5-15) years.

resultsSurvival analysis showed an all-cause 10-year survival rate of the stem of 98.7% (95% CI: 99.7-97.7), and all-cause 10-year survival of the total hip arthroplasty was 98.3% (95% CI: 99.3-97.3).

interpretationExcellent long-term results can be achieved with the cemented Lubinus SP II with the relatively short 130-mm stem. This stem has potential advantages over its 150-mm and 170-mm siblings such as bone preservation distal to the stem, better proximal filling around the prosthesis, and easier removal.

Indexed as

Bone CementsFemurHip ProsthesisProsthesis DesignAgedAged, 80 and overArthroplasty, Replacement, HipCohort StudiesFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLongitudinal StudiesMaleMiddle AgedOutcome Assessment, Health CareBone Cements

Identifiers

PMID24694276
PMCPMC4062795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.